236 related articles for article (PubMed ID: 30663168)
1. Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study.
Ruane P; Strasser SI; Gane EJ; Hyland RH; Shao J; Dvory-Sobol H; Tran T; Stamm LM; Brainard DM; Nyberg L; Shafran S
J Viral Hepat; 2019 Jun; 26(6):770-773. PubMed ID: 30663168
[TBL] [Abstract][Full Text] [Related]
2. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
Bourlière M; Gordon SC; Flamm SL; Cooper CL; Ramji A; Tong M; Ravendhran N; Vierling JM; Tran TT; Pianko S; Bansal MB; de Lédinghen V; Hyland RH; Stamm LM; Dvory-Sobol H; Svarovskaia E; Zhang J; Huang KC; Subramanian GM; Brainard DM; McHutchison JG; Verna EC; Buggisch P; Landis CS; Younes ZH; Curry MP; Strasser SI; Schiff ER; Reddy KR; Manns MP; Kowdley KV; Zeuzem S;
N Engl J Med; 2017 Jun; 376(22):2134-2146. PubMed ID: 28564569
[TBL] [Abstract][Full Text] [Related]
3. Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir.
Younossi ZM; Stepanova M; Gordon S; Zeuzem S; Mann MP; Jacobson I; Bourliere M; Cooper C; Flamm S; Reddy KR; Kowdley K; Younossi I; Hunt S
Clin Gastroenterol Hepatol; 2018 Apr; 16(4):567-574.e6. PubMed ID: 29155352
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
Jacobson IM; Lawitz E; Gane EJ; Willems BE; Ruane PJ; Nahass RG; Borgia SM; Shafran SD; Workowski KA; Pearlman B; Hyland RH; Stamm LM; Svarovskaia E; Dvory-Sobol H; Zhu Y; Subramanian GM; Brainard DM; McHutchison JG; Bräu N; Berg T; Agarwal K; Bhandari BR; Davis M; Feld JJ; Dore GJ; Stedman CAM; Thompson AJ; Asselah T; Roberts SK; Foster GR
Gastroenterology; 2017 Jul; 153(1):113-122. PubMed ID: 28390869
[TBL] [Abstract][Full Text] [Related]
5. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
Wilson E; Covert E; Hoffmann J; Comstock E; Emmanuel B; Tang L; Husson J; Chua J; Price A; Mathur P; Rosenthal E; Kattakuzhy S; Masur H; Kottilil S
J Hepatol; 2019 Sep; 71(3):498-504. PubMed ID: 31173815
[TBL] [Abstract][Full Text] [Related]
6. Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
Bourlière M; Gordon SC; Schiff ER; Tran TT; Ravendhran N; Landis CS; Hyland RH; Stamm LM; Zhang J; Dvory-Sobol H; Subramanian GM; Brainard DM; McHutchison JG; Serfaty L; Thompson AJ; Sepe TE; Curry MP; Reddy KR; Manns MP
Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):559-565. PubMed ID: 29859740
[TBL] [Abstract][Full Text] [Related]
7. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
Sarrazin C; Cooper CL; Manns MP; Reddy KR; Kowdley KV; Roberts SK; Dvory-Sobol H; Svarovskia E; Martin R; Camus G; Doehle BP; Stamm LM; Hyland RH; Brainard DM; Mo H; Gordon SC; Bourliere M; Zeuzem S; Flamm SL
J Hepatol; 2018 Dec; 69(6):1221-1230. PubMed ID: 30098373
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.
Heo YA; Deeks ED
Drugs; 2018 Apr; 78(5):577-587. PubMed ID: 29546556
[TBL] [Abstract][Full Text] [Related]
9. Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.
Chahine EB; Kelley D; Childs-Kean LM
Ann Pharmacother; 2018 Apr; 52(4):352-363. PubMed ID: 29115151
[TBL] [Abstract][Full Text] [Related]
10. Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures.
Pawlotsky JM
Semin Liver Dis; 2019 Jul; 39(3):354-368. PubMed ID: 31041789
[TBL] [Abstract][Full Text] [Related]
11. Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).
Vermehren J; Serfert Y; Cornberg M; Stoehr A; Klinker H; Simon KG; Teuber G; Deterding K; Schulze Zur Wiesch J; Jung MC; Manns MP; Zeuzem S; Wedemeyer H; Sarrazin C
Z Gastroenterol; 2020 Sep; 58(9):841-846. PubMed ID: 32947629
[TBL] [Abstract][Full Text] [Related]
12. Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C.
Voaklander R; Jacobson IM
Expert Rev Gastroenterol Hepatol; 2017 Sep; 11(9):789-795. PubMed ID: 28673106
[TBL] [Abstract][Full Text] [Related]
13. Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection.
Summers BB
Drugs Today (Barc); 2018 Apr; 54(4):255-268. PubMed ID: 29869647
[TBL] [Abstract][Full Text] [Related]
14. Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.
Cory TJ; Mu Y; Gong Y; Kodidela S; Kumar S
Expert Opin Pharmacother; 2018 May; 19(7):749-757. PubMed ID: 29634360
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.
Gane EJ; Kowdley KV; Pound D; Stedman CA; Davis M; Etzkorn K; Gordon SC; Bernstein D; Everson G; Rodriguez-Torres M; Tsai N; Khalid O; Yang JC; Lu S; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Tong M; Chung RT; Beavers K; Poulos JE; Kwo PY; Nguyen MH
Gastroenterology; 2016 Nov; 151(5):902-909. PubMed ID: 27486033
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of pan-genotypic therapies for the treatment of patients with hepatitis C virus infection in Bulgaria.
Djambazov S; Slavchev G; Encheva M; Mitova R; Vekov T
J Comp Eff Res; 2019 May; 8(7):455-459. PubMed ID: 30920311
[TBL] [Abstract][Full Text] [Related]
17. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
Lawitz E; Poordad F; Wells J; Hyland RH; Yang Y; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Landaverde C; Gutierrez J
Hepatology; 2017 Jun; 65(6):1803-1809. PubMed ID: 28220512
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.
Gane EJ; Shiffman ML; Etzkorn K; Morelli G; Stedman CAM; Davis MN; Hinestrosa F; Dvory-Sobol H; Huang KC; Osinusi A; McNally J; Brainard DM; McHutchison JG; Thompson AJ; Sulkowski MS;
Hepatology; 2017 Oct; 66(4):1083-1089. PubMed ID: 28498551
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
Lawitz E; Reau N; Hinestrosa F; Rabinovitz M; Schiff E; Sheikh A; Younes Z; Herring R; Reddy KR; Tran T; Bennett M; Nahass R; Yang JC; Lu S; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Pearlman B; Shiffman M; Hawkins T; Curry M; Jacobson I
Gastroenterology; 2016 Nov; 151(5):893-901.e1. PubMed ID: 27486034
[TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir/velpatasvir/voxilaprevir: a highly effective option for retreatment of hepatitis C in difficult-to-treat patients.
Mathur P; Kottilil S; Wilson E
Antivir Ther; 2019; 24(1):1-10. PubMed ID: 30210057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
